Mylan (MYL) Given a $43.00 Price Target by Wells Fargo & Co Analysts

Mylan (NASDAQ:MYL) has been assigned a $43.00 price objective by Wells Fargo & Co in a research report issued to clients and investors on Thursday, January 18th. The firm presently has a “hold” rating on the stock. Wells Fargo & Co’s price objective would indicate a potential upside of 5.91% from the stock’s previous close.

Other research analysts have also issued reports about the stock. UBS Group reiterated a “buy” rating and set a $46.00 price objective on shares of Mylan in a report on Thursday, October 5th. Instinet reiterated a “buy” rating and set a $37.00 price objective on shares of Mylan in a report on Thursday, October 5th. Citigroup set a $42.00 price target on shares of Mylan and gave the company a “buy” rating in a report on Wednesday, October 4th. Mizuho restated a “buy” rating and issued a $37.00 price target on shares of Mylan in a report on Wednesday, October 4th. Finally, ValuEngine upgraded shares of Mylan from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $44.65.

Shares of Mylan (NASDAQ MYL) opened at $40.60 on Thursday. The stock has a market cap of $21,070.00, a PE ratio of 24.46, a price-to-earnings-growth ratio of 1.06 and a beta of 1.35. Mylan has a 12 month low of $29.39 and a 12 month high of $47.82. The company has a current ratio of 1.46, a quick ratio of 0.95 and a debt-to-equity ratio of 1.05.

In other Mylan news, CEO Heather M. Bresch sold 75,000 shares of Mylan stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total value of $3,375,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.69% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Suntrust Banks Inc. lifted its stake in Mylan by 0.7% in the second quarter. Suntrust Banks Inc. now owns 9,184 shares of the company’s stock valued at $355,000 after buying an additional 60 shares during the last quarter. Wealthsource Partners LLC raised its stake in shares of Mylan by 1.9% during the second quarter. Wealthsource Partners LLC now owns 9,330 shares of the company’s stock valued at $362,000 after purchasing an additional 177 shares in the last quarter. Riverhead Capital Management LLC raised its stake in shares of Mylan by 4.8% during the second quarter. Riverhead Capital Management LLC now owns 7,196 shares of the company’s stock valued at $279,000 after purchasing an additional 328 shares in the last quarter. Gofen & Glossberg LLC IL raised its position in Mylan by 2.4% in the second quarter. Gofen & Glossberg LLC IL now owns 15,194 shares of the company’s stock worth $590,000 after acquiring an additional 360 shares in the last quarter. Finally, Sentry Investment Management LLC raised its position in Mylan by 1.1% in the second quarter. Sentry Investment Management LLC now owns 34,290 shares of the company’s stock worth $1,331,000 after acquiring an additional 360 shares in the last quarter. Institutional investors own 75.56% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Mylan (MYL) Given a $43.00 Price Target by Wells Fargo & Co Analysts” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/13/wells-fargo-co-analysts-give-mylan-myl-a-43-00-price-target.html.

About Mylan

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply